Core Insights - The company reported a revenue of 4.457 billion yuan and a net profit of 72.3782 million yuan for the first half of 2025, marking a year-on-year growth of 15.11% [1] Group 1: Business Transformation - The company is shifting its strategy from "meeting customer needs" to "stimulating customer demand" amidst a decline in customer traffic and average transaction value in the pharmaceutical retail industry [1] - The company is reducing its reliance on medical insurance and is deepening its transformation towards health products, specialized services, and omnichannel marketing [1] Group 2: Cost Control and Efficiency - The company has achieved a reduction in operating expenses, with a year-on-year decrease of 0.83% in total expenses for the first half of the year [1] - Continuous control over store rental, promotional, distribution, and management expenses has contributed to reversing the trend of increasing store costs [1]

此外，公司还荣获"2025中国药品零售城市群竞争力十强——山东中部城市群十强企业"称号。这一奖项由中康产业研 究院基于连锁销售潜力模型，从多维度对全国24个核心城市群的药品零售企业进行全面评估后选出，体现了信宏仁在 区域协同、战略布局与服务创新方面的卓越表现。 信宏仁医药董事长张超获"2025年度药品零售行业觉醒者"称号。该奖项旨在表彰在医药零售领域推动转型、具有前瞻 视野与创新实践的领军人物。张超自2003年创办企业以来，带领信宏仁医药稳步发展，融合先进管理模式，逐步成长 为区域领先的药品零售企业，并成功跻身全国百强连锁行列。 同时，信宏仁医药成功入选"2025中国药品零售综合竞争力百强榜"，位列第39名。该榜单覆盖全国27个省份（自治 区、直辖市），竞争激烈，综合评估企业在规模、盈利、运营、成长性等多维度的实力。 8月17日至18日，西普会（中国健康产业生态大会）在海南博鳌举行，山东信宏仁医药连锁有限公司凭借卓越的企业 实力与战略布局，一举斩获三项行业重磅荣誉，成为本届大会瞩目的焦点之一。 面对医药健康行业的深刻变革，信宏仁医药将继续坚持以顾客满意为核心，不断提升专业服务水平，强化区域布局， 致力于成为医 ...